stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Total debt
BioMarin Pharmaceutical Inc.'s total debt at the end of fiscal 2025 was $597.2M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $4.2B. Over the past ten years it has ranged from $595.1M (fiscal 2024) to $1.2B (fiscal 2017); the current reading is higher than 18% of that period. BioMarin Pharmaceutical Inc. ranks 4th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $597.2M | 0.34% |
| FY2024 | $595.1M | (45.25%) |
| FY2023 | $1.1B | (0.55%) |
| FY2022 | $1.1B | 0.36% |
| FY2021 | $1.1B | 0.18% |
| FY2020 | $1.1B | 28.18% |
| FY2019 | $848.1M | 2.13% |
| FY2018 | $830.4M | (29.29%) |
| FY2017 | $1.2B | 71.90% |
| FY2016 | $683.2M | 3.16% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $4.2B | (0.30%) |
| Jun 2026 | $4.2B | 192.68% |
| Mar 2026 | $1.4B | 139.51% |
| Dec 2025 | $597.2M | 0.09% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. | $4.2B |
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| PCVX Vaxcyte, Inc. compare | $14.0M |
| KYMR Kymera Therapeutics, Inc. compare | $602.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement